• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Macro Australian Economy

Why Tech Stocks Are Doing So Well and Where to Look for the Next Amazon

Like 0

By Lachlann Tierney, Wednesday, 02 September 2020

Increasingly gains on the S&P 500 [SPX] are concentrated in the hands of just a few companies. There’s a good reason for this — the pandemic is accelerating the push towards technology like never before. But there are two perspectives out there, which offer very different visions of what the market will do...

Everyone knows the FAANG (or FAMGA) club is doing extremely well during this mess.

And although it’s not officially in the club, Tesla Inc [NASDAQ:TSLA] may be the pick of the bunch.

Increasingly gains on the S&P 500 [SPX] are concentrated in the hands of just a few companies.

There’s a good reason for this — the pandemic is accelerating the push towards technology like never before.

But there are two perspectives out there, which offer very different visions of what the market will do in the coming months.

 

Bears and value versus big tech bulls — and my view

In the bear corner, you’ve got people who think a double-dip crash is on the way and that we are approaching dotcom-level valuations on big tech.

A follow up to this view would say something like, ‘Big tech is now a defensive play, positions in these stocks allow investors and funds to exit quickly should the market tank.’

Value is the name of the game for these bears.

So, let’s take a look at little-known US fund, the Invesco S&P 500® Equal Weight ETF [RSP].

RSP is an equal weight ETF, meaning it is spread across the 500 companies evenly as opposed to being based on market capitalisation.

Size doesn’t matter with this one.

It’s underperforming the S&P 500 significantly, as you would expect given the run tech companies are on (RSP blue line, SPX red line):


Port Phillip Publishing

Source: tradingview.com

[Click to open in a new window]

[conversion type=”in_post”]

To the value hunters and bears this means that tech looks expensive and everything else looks cheap.

There will be a cyclical shift to value, as the economy recovers, and non-tech companies will get their day in the sun once more.

In the bull corner though, are those that think big tech is just getting started and that their dominant position in our lives is never going to change.

My view is a bit more nuanced.

Anyway, here it is:

  1. Big tech stocks like FAMGA are at the tail end of a ‘mature’ megatrend
  2. As a result, and given their massive cash reserves, you should be looking for the next megatrend
  3. The companies that ride the next megatrend could become acquisition targets or go on their own Amazon-like run up the charts
  4. Consequently, you should be looking at smaller tech companies in certain areas
  5. Tech stocks are never going away; you just need to be smarter when picking them

Where to look for the next Amazon-like tech stock run

In the immediate future, I’m looking closely at healthcare.

It sounds counter-intuitive, but it’s not.

You may say:

‘Don’t you know there is a pandemic on? Healthcare is getting crushed!’

First of all, that’s simply not the case.

Check out the S&P ASX 200 Healthcare Index [XHJ]:


Port Phillip Publishing

Source: tradingview.com

[Click to open in a new window]

It’s holding up remarkably well from the March market lows.

Secondly, when I say healthcare, I mean medtech (medical technology) more precisely.

Not the big insurance companies or the private hospitals, but the companies bringing efficiency to the sector with new products and services.

I’ve covered the exciting world of medtech stocks before.

But the point remains.

Increasingly, the FAMGA stocks are looking at these types of companies.

FAMGA is at the tail end of the megatrend which was the world going online.

So naturally, they are looking for the next big thing, or else they will become dinosaurs.

This is now Australia’s biggest manufacturing export

I’d also note that Australia is well-placed to lead in the medtech race.

Check this from the Australian Financial Review (emphasis added):

‘It is clear COVID-19 is going to have a profound impact on ambitious state and federal plans to establish Australia as an Asia-Pacific hub for medical technology and pharmaceutical companies.

‘Before COVID-19 arrived, a far-reaching program to develop the MTP sector had centred around a series of growth funds, focussed on pharmaceutical research translation, device development and biotechnology investment.

‘MTP Connect was established in 2015 to drive the program and has overseen more than $100 million invested through the growth funds. The budget for the funds has come from earnings from the nearly $20 billion national medical research fund and was part of a determined push for Australia to leverage its high-class health infrastructure and services.

‘At the same time, state governments have also invested strongly in the sector, with the Victorian government especially focussed on building a large-scale Silicon Valley-like precinct, centred on its world-leading research capability around Melbourne and Monash universities.

‘According to the managing director of Brandon Capital, Dr Chris Nave, the pharmaceutical and medical products market is now Australia’s largest manufacturing export, with an estimated $8.2 billion.’

You read that correctly, pills and medical products are now our biggest manufacturing export.

We can’t make cars, whitegoods, or steel like developing countries can, but we do medtech and pills extraordinarily well.

It’s a combination of a highly educated workforce, top-of-the-line research institutions, and a little help from the taxman.

After we extricate ourselves from this pandemic quagmire, this part of the Australian economy is poised to grow even further.

That’s because the backlog of patients and inefficiencies will need to be addressed somehow.

The imminent ‘Health Revolution’ is a big theme in our Exponential Stock Investor service.

I’d encourage you to learn more about it.

Regards,

Lachlann Tierney Signature

Lachlann Tierney,
For Money Morning

PS: Three Exciting Tech Trends and Three Small-Cap Stocks that could Explode in 2020. Claim Your Free Report.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney
Lachlann ‘Lachy’ Tierney is passionate about uncovering hidden opportunities in the microcap sector. With four years of experience as a senior equities analyst at one of Australia’s leading microcap firms, he has built a reputation for rigorous research, deep-dive due diligence, and accessible investor communications. Over this time, he has vetted seed, pre-IPO and ASX-listed companies across sectors, conducted onsite visits, and built strong relationships across the microcap space. Lachy is nearing completion of a PhD in economics at RMIT University, where his research focuses on blockchain governance and voting systems. His work is housed within the Blockchain Innovation Hub at RMIT, a leading research centre for crypto-economics and blockchain research. He holds a Master’s degree from the London School of Economics and an Honours BA in Philosophy and Politics from the University of Melbourne. Born in New York and raised in California, Lachy grew up a few blocks from biotech giant Amgen and counts among his peers various characters in the overlapping worlds of venture capital, technology and crypto. When he’s not researching microcaps, he’s most likely sweating it out in a sauna or dunking himself in cold Tasmanian water.

Lachlann’s Premium Subscriptions

Publication logo
Australian Small-Cap Investigator
Publication logo
Fat Tail Microcaps
Publication logo
James Altucher’s Early-Stage Crypto Investor Australia

Latest Articles

  • Retrospective Pt. 1 (Lithium): Our best coverage this year
    By Lachlann Tierney

    After years in the wilderness, lithium is finally showing signs of life. The sector has been absolutely decimated since its 2022 peak, with prices still about ~85% below those highs. But the narrative is shifting in a profound way, and I firmly believe early positioning in quality lithium companies could pay off handsomely over the next 12 to 24 months.

  • As markets Detach from Reality, Focus on Stocks Producing Real Things
    By James Cooper

    Cheap resource companies producing real things, that’s what James Cooper detailed at his recent presentation at the Noosa Mining Conference last month.

  • The Canary is Coughing
    By Charlie Ormond

    US employment data has long served as an early warning system for the global economy. When American workers start losing jobs, trouble tends to follow…For markets, for Australia, and eventually for your portfolio.

Primary Sidebar

Latest Articles

  • Retrospective Pt. 1 (Lithium): Our best coverage this year
  • As markets Detach from Reality, Focus on Stocks Producing Real Things
  • The Canary is Coughing
  • The Backdoor Entry: Why Majors Buy 10% Stakes Years Before 100% Takeovers
  • Copper’s Christmas Breakout and a New Stock Idea

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988